CSIMarket Company Name, Ticker, Customers, else..
 
Sigyn Therapeutics Inc   (RSAP)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Sigyn Therapeutics Inc
Sigyn Therapeutics Inc is a pharmaceutical company focused on developing novel therapies for the treatment of inflammatory diseases. Their primary focus is on the development of Sigyn Therapy, a proprietary drug that aims to reduce inflammation and promote tissue regeneration. This therapy is designed to be applicable to a wide range of conditions, including autoimmune diseases, acute organ injuries, and chronic inflammatory conditions. Sigyn Therapeutics Inc is dedicated to bringing innovative solutions to healthcare and improving the lives of patients suffering from inflammatory diseases.


   Company Address: 2468 Historic Decatur Road Ste. San Diego 92106 CA
   Company Phone Number: 353-0800   Stock Exchange / Ticker: RSAP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AEMD   -1.81%    
CRBU        2.54% 
IOVA        1.3% 
• View Complete Report
   



Sigyn Therapeutics Inc

Sigyn Therapeutics Inc Faces Escalating Business Costs in Second Quarter of 2023 as Industry Challenges Mount

In the Medical Equipment & Supplies sector, while the focus has been on the major players, there are some overlooked entities that have recently published their financial results. One such entity is RSAP, which has reported an operating shortfall of $-0.574009 million for the second quarter of 2023. Although the company has not yet disclosed its top-line figures, we can gain a better understanding of the recent performance by comparing it to the second quarter of 2022.
In the second quarter of 2022, RSAP reported an operating shortfall of $-0.532795 million. Therefore, it is evident that the company's operating shortfall has increased in the second quarter of 2023, as compared to the previous year. The recent shortfall of $-0.723 million is substantially higher than the $-0.666 million reported in the same period of 2022. This widening deficit could raise concerns about the company's financial performance and prospects.
Sigyn Therapeutics Inc

Sigyn Therapeutics Inc Makes a Mark With Innovative Therapies, but Faces Financial Challenges in Q1 2023

Sigyn Therapeutics Inc: A Rising Entity in the Medical Equipment and Supplies Industry
The medical equipment and supplies industry has been one of the fastest-growing industries in recent years, marked by the rise of innovative medical technologies and solutions. Sigyn Therapeutics Inc is a company that has been making a name for itself in this competitive industry. The company is focused on developing novel therapies for the treatment of life-threatening diseases and medical conditions.
However, the company's first quarter results for 2023 have raised a few concerns among industry reporters. The operating deficit of $-0.521258 million is a cause for alarm, especially since the company has not specified any top-line earnings for the respective January to March 31, 2023, financial reporting period. The net loss has also swelled to $-1.341 million, a significant increase from the same period in 2021.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com